Brianne Jahn
Corporate Officer/Principal at LIANBIO
Net worth: 69 397 $ as of 2024-04-29
Brianne Jahn active positions
Companies | Position | Start | End |
---|---|---|---|
LIANBIO | Corporate Officer/Principal | 2021-08-31 | - |
Chief Operating Officer | 2020-01-31 | 2021-08-31 | |
Director of Finance/CFO | 2020-01-31 | 2021-04-30 | |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Director/Board Member | - | - |
Career history of Brianne Jahn
Former positions of Brianne Jahn
Companies | Position | Start | End |
---|---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 2012-03-31 | 2019-12-31 |
Training of Brianne Jahn
University of Massachusetts | Undergraduate Degree |
New York University | Masters Business Admin |
Statistics
International
United States | 5 |
China | 2 |
Operational
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
LIANBIO | Health Technology |
Private companies | 2 |
---|---|
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Brianne Jahn
- Experience